Cardiac Allograft Remodeling and Effects of Sirolimus
Status:
Suspended
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
Cardiac allograft remodeling causes poor quality of life, allograft failure and increased
mortality after heart transplantation. Risk factors for cardiac allograft remodeling and its
progression are poorly defined and there is a need for effective interventions.This is a
multi-factorial phenomenon, associated with various immunological and non-immunological
factors. Animal studies suggest M-TOR inhibition attenuates cardiac allograft remodeling
secondary to down-regulation of M-TOR downstream targets and increased autophagy. There is a
paucity of data regarding effect of Sirolimus, a M-TOR inhibitor, on human heart remodeling.
This aim of the proposal to identify the prevalence of cardiac allograft remodeling on
current immunosuppressive strategies and determine risk factors for its development. It will
also identify molecular pathways associated with cardiac allograft remodeling and determine
the impact of Sirolimus on these pathways.